TG Therapeutics (NASDAQ: TGTX) reported Q3 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $83.3 million versus the consensus estimate of $81.21 million.

2024 Updated Target U.S. BRIUMVI Guidance

Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024 (prior guidance of $290 to $300 million for full year 2024)

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.